High Frequency of HBeAg-Negative Cases in Naive HBsAg-Positive Subjects with Chronic Hepatitis B Virus Infection Managed in the Yaoundé Hepatitis Therapeutic Committee: A Cross Sectional Study

Firmin Ankouane*, Mathurin Kowo, Oudou Njoya, Elie Claude Ndjitoyap Ndam

Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon
Email: ankouaneandoulo@yahoo.com

Received 28 March 2015; accepted 4 May 2015; published 12 May 2015

Copyright © 2015 by authors and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY).
http://creativecommons.org/licenses/by/4.0/

Abstract

The aim was to describe the epidemiology of the chronic hepatitis B virus (HBV) infection within Yaoundé Hepatitis Therapeutic Committee. Methods: This was a cross-sectional study from June 2004 to May 2012. We consecutively collected epidemiological data (gender, age, alanine amino-transferase-ALT, HBe-antigen-HBeAg, hepatitis B viral load-HBV-DNA and cirrhosis evaluation) from naive hepatitis B surface antigen (HBsAg)-positive patients with chronic HBV infection. Chronic HBV infection is defined by the persistence of HBsAg for at least six months. The level of serum HBV-DNA was determined by the COBAS-AmpliPrep Technical/COBAS-TaqMan HBV® 2.0 (Roche). Data were entered and analyzed using SPSS 20.0 software (IBM Corporation, USA). Results: Of the 315 HBsAg-positive patients consulted, 74.6% were male; mean (SD) age 35.04 (10.25) years. Nearly 92% were HBeAg-negative. The serum ALT level was normal in 63.2%; HBV-DNA was detected in 81.0% and was ≤2000 IU/mL in 65.9%. Liver biopsy was performed in 145 (46.03%); 10 (6.9%) had cirrhosis. HBeAg-negative patients were older than HBeAg-positive (35.3 vs. 31.9 years; p = 0.006). The serum ALT level was high in 84.0% HBeAg-positive patients and in 32.8% HBeAg-negative (p < 0.0001). HBV-DNA was detected in 100% of HBeAg-positive patients against 79.7% of HBeAg-negative (p = 0.05). The median HBV-DNA level was 1550 × 10^3 IU/mL in HBeAg-positive patients and 1140 IU/mL in HBeAg-negative (p < 0.0001). Cirrhosis was diagnosed in 15.4% of HBeAg-positive patients and in 6.1% of HBeAg-negative (p = 0.221). Conclusion: HBeAg-negative cases are predominant among HBsAg-positive patients with chronic HBV infection in

How to cite this paper: Ankouane, F., et al. (2015) High Frequency of HBeAg-Negative Cases in Naive HBsAg-Positive Subjects with Chronic Hepatitis B Virus Infection Managed in the Yaoundé Hepatitis Therapeutic Committee: A Cross Sectional Study. Open Journal of Epidemiology, 5, 113-121. http://dx.doi.org/10.4236/ojepi.2015.52015
1. Introduction

Cameroon, like many countries in Sub-Saharan Africa, is in a highly endemic area for the hepatitis B virus (HBV) infection. Indeed, epidemiological data from the World Health Organization (WHO) suggest that in Cameroon 8% - 20% of the general population, or 1.6 to 4 million people are infected with HBV [1]. In the 2000s, the country adopted strategies against HBV transmission, such as the Expanded Program on Immunization including the HBV vaccine at 6 weeks of life, and the Protection from the mother to Child Transmission. Nevertheless, social and regional gaps are observed in the prevalence of the infection and in the treatment of hepatitis. Two reference Hepatitis Therapeutic Committees including the Yaoundé Committee, have been set up for the 10 regions of Cameroon.

Yaoundé, the political capital of Cameroon, is located in the central region. It covers 304 km² and hosts a cosmopolitan population, estimated in 2005, during the 3rd population and habitat census of March 2010, at 1,817,524 inhabitants. Two Cameroonians out of three are considered as living in cities. Yaoundé is endowed with three first category hospitals making up the Yaoundé Reference Hepatitis Therapeutic Committee.

In the world, despite vaccination programs against HB and other effective preventive measures, more than 350 million people are affected and among them, 25% of cases may during their lives develop hepatocellular deficiency, cirrhosis and hepatocellular carcinoma [2]-[4]. Every year in the world, 500,000 to 1,200,000 deaths are also attributable to HBV complications, mainly in Asia and Sub-Saharan Africa [2] [5]. The prognosis of the disease is related to the characteristics of the HBV infection. Thus, the prognosis of HBe antigen-negative chronic hepatitis is poor, with only a few rare cases of spontaneous remission and a low sustained response rate to antiviral treatment [6] [7]. The percentage of patients with chronic hepatitis B who are HBeAg-negative is increasing in the world with 80% - 90% in Mediterranean areas, 20% - 87% in France, 30% - 50% in Southeast Asia and less than 10% in the United States of America and North Western Europe [2] [8]-[12].

These considerations notwithstanding, the characteristics of chronic HBV infection are not well defined in Cameroon. This ignorance is a missed opportunity for the effective case management of the disease in our country. This study used data from patients in the three hospitals constituting the Yaoundé Hepatitis Therapeutic Committee.

This eight-year cross-sectional descriptive study of care management for patients with chronic HBV infection in Yaoundé was to describe the epidemiological, biological and histological characteristics of these patients in order to optimize their care.

2. Materials and Methods

2.1. Definition of Cases and Collected Variables

Consenting consecutive HB surface antigen (HBsAg)-positive patients with chronic HBV infection and naive of antiviral treatment, consulted by gastroenterologists during the study period were eligible for the study. Chronic HBV infection is defined by the persistence of HBsAg for at least six months. This cross-sectional descriptive study was conducted from June 1, 2004 to May 31, 2012 in three hospitals in Yaoundé, Cameroon, constituting the Yaoundé Hepatitis Therapeutic Committee, by members of the Network of the Cameroon Society of Gastroenterology: Société Camerounaise de Gastroentérologie (SCGE).

The main epidemiological features (age, gender, screening date for HBsAg, alcohol abuse > 80 g/d), biological tests (alanine aminotransferase (ALT), HB viral load (HBV DNA levels), HBeAg status, hepatitis C virus status (HCV), Delta virus (HDV), human immunodeficiency virus (HIV)), as well as the morphology of the liver (fibrosis evaluation and cirrhosis evaluation by liver biopsy and/or fibrotest) were collected. The search for HBsAg was performed by 3rd generation ELISA, DIA-HBV® commercial kit (DiaProph.Med, Ukraine, Russia).
The results were positive if the optical density (OD) of the test sample was greater than the OD threshold. The test was negative if the OD level was greater than the OD test sample. The HBeAg, anti-HBe antibodies, anti-HCV antibodies were detected by ELISA (Biomerieux Clinical Diagnostics, Geneva, Switzerland). The anti-delta antibodies were detected by EIA reactive sold by Adaltis (Rome, Italy). The level of serum HBV-DNA was determined by the COBAS AmpliPrep Technical/COBAS TaqMan HBV 2.0 Roche (Meylan, France) with a positivity threshold of 20 IU/mL (linearity of 20 IU/mL to 170 million IU/mL). Biochemical tests used to calculate the fibrotest/Actitest were made with Roche reagents (Meylan, France) on the Roche COBAS machine. The calculation of fibrosis scores was done by the website of the company Biopredictive (www.biopredictive.com) in favor of the laboratory Cerba, 95066 Cergy Pontoise Cedex 9 France (www.lab-cerba.com). Liver biopsy was performed according to the conventional subcostal trans-parietal technique under local anesthesia with lidocaine hydrochloride 1% by a gastroenterologist. Histology was performed at Centre Pasteur of Cameroon, Yaoundé.

The HBV DNA level was classified ≤2000 IU/mL and >2000 IU/mL, the HBV DNA was detectable at the threshold of 20 IU/mL, the fibrosis score according to METAVIR [13] was classified ≤F1 and >F1, F1 matching portal fibrosis without septa, and serum alanine aminotransferase (ALT) levels were classified in two groups of patients (1 × Upper Limit of normal (ULN) < ALT < 2 × ULN, normal ALT group and ALT ≥ 2 × ULN, elevated ALT group). The HBsAg-positive patients discovered under 6 months, the HBsAg-positive patients/positive anti-delta, HBeAg-positive/anti-HBe positive, HBeAg-negative/anti-HBe negative were not considered. Similarly co-infected HIV patients and patients with other causes of liver disease (e.g. Alcohol, metabolic, autoimmune) were excluded from the study.

2.2. Statistical Analysis
The data analyses were performed using SPSS 20.0 software (IBM SPSS Statistics, IBM Corporation, Armonk, NY, USA) and Microsoft Excel 2007. For quantitative variables, the means and standard deviations, medians and interquartile (IQR) were calculated. The proportions were established for categorical variables with their confidence intervals (CIs) at 95%.

Comparisons of proportions were performed using Chi² or Student test. Yates correction and the Fisher exact test were used for small numbers (at least 5). The significance level was set at 5%.

3. Results
3.1. General Characteristics of Patients (Table 1)
Between 2004 and 2012, 328 HBsAg-positive patients with chronic HBV infection were analyzed. Out of these, 315 met the inclusion criteria. Mostly, there were men (74.6%) and patients in the age group 20 - 39 years (65.1%). The mean age (±SD) of HBsAg-positive patients was 35.04 ± 10.25 years. The men were older than women (mean age of men 35.5 years and 33.8 years for women; p = 0.338).

The HBeAg was negative for 92.1% [95%CI 88.4 - 94.7] patients. The serum ALT level was elevated for 36.8% [95%CI 31.5 - 42.4] patients, this varied according to the gender (16.4% in female and 83.6% in male; p = 0.005). The HBV DNA was detected in 81.0% [95%CI 75.6 - 85.6] of HBsAg-positive patients. It was >2000 UI/mL for 34.1% [95%CI 28.3 - 40.3], this result varied depending on serum ALT levels (46.6% in patients with high serum ALT levels and 27.4% in patients with normal serum ALT levels, p = 0.002) and gender (17.9% in female and 33.3% in male; p = 0.04), while age did not influence the hepatitis B viral load (p = 0.688).

A liver biopsy alone or combined with Fibrotest was performed in 46.0% patients and Fibrotest alone or associated with liver biopsy was performed in 47.6% patients. A METAVIR score > F1 was found in 49.3% [95%CI 41.1 - 57.6] Fibrotest patients, while cirrhosis was diagnosed in 6.9% [95%CI 3.4 - 12.3] patients with liver biopsy. This varied with the age of patients (0% in <20 years, 2.4% in 20 - 39 years, 4.6% in 40 - 59 years and 33.3% in ≥60 years; p = 0.077). Gender had no influence on the presence of cirrhosis (3.3% in women and 7.8% in men, p = 0.687).

3.2. Comparison between HBeAg-Negative and HBeAg-Positive Patients (Table 2)
There were 25 (7.9%) HBeAg-positive patients and 290 (92.1%) HBeAg-negative patients. The HBeAg-negative patients were significantly older than HBeAg-positive patients (35.3 years and 31.9 years, respectively; p = 0.006). No difference in the male/female ratio was observed between HBeAg-positive patients and HBeAg-
### Table 1. General features of HBsAg-positive patients in Yaoundé, Cameroon (n = 315).

<table>
<thead>
<tr>
<th>Features</th>
<th>Results</th>
<th>Percentage (%)</th>
<th>95% Confidence Intervals</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20 years</td>
<td></td>
<td>6.0</td>
<td>3.8 - 9.4</td>
</tr>
<tr>
<td>20 - 39 years</td>
<td></td>
<td>65.1</td>
<td>59.5 - 70.3</td>
</tr>
<tr>
<td>40 - 59 years</td>
<td></td>
<td>27.9</td>
<td>23.1 - 33.3</td>
</tr>
<tr>
<td>≥60 years</td>
<td></td>
<td>1.0</td>
<td>0.2 - 3.0</td>
</tr>
<tr>
<td><strong>Male gender</strong></td>
<td></td>
<td>74.6</td>
<td>69.4 - 79.2</td>
</tr>
<tr>
<td><strong>ALT ULN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2</td>
<td></td>
<td>63.2</td>
<td>57.6 - 68.5</td>
</tr>
<tr>
<td>≥2</td>
<td></td>
<td>36.8</td>
<td>31.5 - 42.4</td>
</tr>
<tr>
<td><strong>HBV DNA levels (IU/mL)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2000</td>
<td></td>
<td>65.9</td>
<td>59.7 - 71.7</td>
</tr>
<tr>
<td>&gt;2000</td>
<td></td>
<td>34.1</td>
<td>28.3 - 40.3</td>
</tr>
<tr>
<td><strong>Liver fibrosis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤F1</td>
<td></td>
<td>50.7</td>
<td>42.4 - 58.9</td>
</tr>
<tr>
<td>&gt;F1</td>
<td></td>
<td>49.3</td>
<td>41.1 - 57.6</td>
</tr>
<tr>
<td><strong>Liver cirrhosis</strong></td>
<td></td>
<td>6.9</td>
<td>3.4 - 12.3</td>
</tr>
<tr>
<td>HBeAg**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td></td>
<td>7.9</td>
<td>5.3 - 11.6</td>
</tr>
<tr>
<td>Negative</td>
<td></td>
<td>92.1</td>
<td>88.4 - 94.7</td>
</tr>
<tr>
<td><strong>HBV DNA detectable</strong></td>
<td></td>
<td>81.0</td>
<td>75.6 - 85.6</td>
</tr>
</tbody>
</table>

*Mean ± standard deviation; †Alanine aminotransferase, upper limit of normal; ‡Hepatitis B virus DNA; §METAVIR score on 150 patients; F1: portal fibrosis without septa; ‖Liver biopsy on 145 patients; **Hepatitis B e antigen.

### Table 2. Epidemiological, biological and histological features of HBeAg-positive patients and HBeAg-negative patients in Yaoundé, Cameroon.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients HBeAg status</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HBeAg-positive</td>
<td>HBeAg-negative</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>31.9 ± 14.3</td>
<td>35.3 ± 9.8</td>
</tr>
<tr>
<td>&lt;20 years (%)</td>
<td>20.0</td>
<td>4.8</td>
</tr>
<tr>
<td>20-39 years (%)</td>
<td>52.0</td>
<td>66.2</td>
</tr>
<tr>
<td>40-59 years (%)</td>
<td>28.0</td>
<td>27.9</td>
</tr>
<tr>
<td>≥60 years (%)</td>
<td>0.0</td>
<td>1.0</td>
</tr>
<tr>
<td><strong>Female gender (%)</strong></td>
<td>16.0</td>
<td>26.2</td>
</tr>
<tr>
<td><strong>ALT ULN</strong></td>
<td>84.0</td>
<td>32.8</td>
</tr>
<tr>
<td>≥2</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Liver histology (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver fibrosis‡ &gt; F1</td>
<td>69.2</td>
<td>47.4</td>
</tr>
<tr>
<td>Liver cirrhosis§</td>
<td>15.4</td>
<td>6.1</td>
</tr>
<tr>
<td><strong>HBV DNA levels (IU/mL) (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;2000</td>
<td>100</td>
<td>29.7</td>
</tr>
<tr>
<td><strong>HBV DNA detectable (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥10^3</td>
<td>100</td>
<td>79.7</td>
</tr>
<tr>
<td><strong>HBV DNA levels (IU/mL)</strong>†</td>
<td>1550 × 10^3</td>
<td>1140</td>
</tr>
</tbody>
</table>

*Mean ± standard deviation; †Alanine aminotransferase, upper limit of normal; §METAVIR score on 150 patients; F1: portal fibrosis without septa; ‖Liver biopsy on 145 patients; ‡Hepatitis B virus DNA; ††Median hepatitis B viral load.
negative patients. The serum ALT level was higher for 84.0% of HBeAg-positive patients and 32.8% of HBeAg-negative patients ($p < 0.0001$). Among HBeAg-positive patients, 100% had detectable HBV DNA, while 79.7% of HBeAg-negative patients had detectable HBV DNA. The detectable HBV DNA proportion was significantly higher in patients with elevated serum ALT levels compared to patients with normal serum ALT levels, especially in HBeAg-positive cases. The median hepatitis B viral load was low among HBeAg-negative patients compared to HBeAg-positive patients ($p < 0.0001$), of these 100% had a hepatitis B viral load > 2000 UI/mL ($p < 0.0001$).

From the point of view of the severity of liver injury, fibrosis METAVIR score > F1 was found in 69.2% of HBeAg-positive patients and in 47.4% of HBeAg-negative patients without this difference being significant ($p = 0.226$). Similarly cirrhosis was diagnosed in 15.4% HBeAg-positive patients and in 6.1% HBeAg-negative patients ($p = 0.221$). Men were more often severely affected than women (7.8% vs. 3.3%; $p = 0.687$).

4. Discussion

This is a descriptive study of a population of 315 HBsAg-positive patients with chronic HBV infection consulted by Cameroonian gastroenterologists in the first category hospitals of Yaoundé. At first glance it is difficult to generalize the results of this study in the overall population. There are inequalities in the prevalence of HBsAg among regions of Cameroon, and there are also social inequalities. Nevertheless, this study has the merit of being to our knowledge the first ever study addressing the issue in our environment.

This study gives us an opportunity to describe HBsAg-positive patients with chronic HBV infection and unaware of antiviral treatment, supported by a reference Hepatitis Therapeutics Committee. Knowledge is essential to optimize the care of patients. In this study HBsAg-positive patients were predominantly men in the age group of 20 - 39 years with an average age of 35.04 years and a predominant frequency of HBeAg-negative cases (92.1%). Also, the majority of HBsAg-positive patients had normal serum ALT levels (63.2%), a HB viral load level $\leq 2000$ UI/mL (65.9%) and severe liver histological lesions at cirrhosis in 6.9% cases at the time of the consultation.

To grasp the significance of the results of this study, it is useful to know that the distribution of academic hospitals that can handle cases of chronic HB is uneven in Cameroon. Thus, these hospitals are concentrated in Yaoundé and Douala. Therefore, these two cities drain almost all the patients treated for chronic HB in the 10 regions of Cameroon, which enables us to generalize our results. Subsequently, the majority of cases of viral HB observed in Sub-Saharan African countries, including in Cameroon have been at the stage of chronicity, because of the early horizontal predominant contamination mode, mostly due to children being infected during early childhood [14]-[16]. Indeed, the passing to chronicity rate is highly influenced by the mode of transmission. Thus, the risk of chronicity is more common and almost systematic (90%) in the new-borns from infected mothers and 25% - 30% in children under 5 [14] [16]. These observations justify the status of chronic infection employed among our patients.

The results of this study are similar to those of the study we previously conducted with a population of workers [17]. They are also similar to results of previous studies in our country [18] [19] and various countries in Sub-Saharan Africa, particularly in Burkina Faso [20], Ghana [21] and Ivory Coast [22]. These various studies showed that the prevalence of HBsAg was higher in men than in women and among people less than 40 years compared with older subjects.

Most patients with chronic HBV infection managed by the Yaoundé Hepatitis Therapeutic Committee are HBeAg-negative (92.1%). This proportion is higher than that observed in Ouagadougou, Burkina Faso (88.6%) [23], Algeria (87%) [24], France (87%) [11], Italy (86.4%) [12] and Southeast Asia (30% - 50%) [2]. Thus, chronic HBeAg-negative hepatitis became over time the major form of chronic HBV infections in many countries [11] [25]. In the Western world, this trend is due to the migration of populations where this form affects the majority of people, especially from the Maghreb countries to the West. Therefore, it is explained by the anti-HBV vaccination coverage of the population and the specific antiviral treatments available in developed countries [26] [27]. In the African context, especially in Sub-Saharan Africa, the prevalence of HBeAg-negative cases would be the result of the natural course of the disease by HBeAg seroconversion, with disappearance of the HBeAg and the appearance of anti-HBe antibodies, and on the other hand by aging chronic HBV carriers subjects in the population [2] [14]. These chronic carriers in our environment are often contaminated during infancy by horizontal transmission [14] [28] [29]. The delay in the broadly implementation of vaccination programs at
birth in several Sub-Saharan Africa also explains the evolution of the disease [14] [28].

This study is the first comparison of the HBeAg-positive patients and the HBeAg-negative ones in a hospital based study. Previous studies conducted in our country and dealing with the problem targeted a population of pregnant women [30]-[32]. They nevertheless provide useful information. The prevalence of HBeAg is variously reported in these studies. The study of Kfutwal et al. [30] included pregnant women of an average age of 26.2 years and no case of HBeAg-positive was found. In that of Fomulu et al. [31] pregnant women had an average age of 26.9 years and the authors reported a prevalence of HBeAg of 28%. Finally, Ducancelle et al. [32] included pregnant women with an average age of 24.5 years in their study and reported a prevalence of HBeAg of 22%. In our study, the overall prevalence of HBeAg was 7.9% and the specific prevalence of HBeAg related to the consultation have been defined by a profile. Those with fluctuations in viral replication and transaminases levels at relatively high rates (29.7%) and elevated serum ALT levels (32.8%) above the standard at the time of inclusion pregnant women with an average age of 26.2 years and no case of HBeAg-positive was found. In that of Fomulu et al. [31] pregnant women had an average age of 26.9 years and the authors reported a prevalence of HBeAg of 28%. Finally, Ducancelle et al. [32] included pregnant women with an average age of 24.5 years in their study and reported a prevalence of HBeAg of 22%. In our study, the overall prevalence of HBeAg was 7.9% and the specific prevalence of HBeAg related to the female gender was 5%. None among the patients was pregnant and the average age was 33.8 years. This specific prevalence was higher in patients less than 20 years (12.5%) and the female gender was 5%. None among the patients was pregnant and the average age was 33.8 years. This specific prevalence was higher in patients less than 20 years (12.5%) and lower in patients between 20 - 39 years (3.8%), 40 - 59 years (5.0%) and none among patients of 60 and over. The influence of age in the HBeAg seroconversion is known [33] [34]. So Candotti et al. [35] reported that HBeAg seroconversion appeared in Sub-Saharan Africa in adolescents before the age of 15 - 16 years, which is different from the age of onset of HBeAg seroconversion in Asia, in average 30 - 35 years with 90% of cases before age 40 [34]. Subjects with early HBeAg seroconversion therefore are older, have an older infection and rather carry genotypes A, B, D and F than genotype C [7] [36] [37]. Genotype A (A1 and A3) is predominant in Africa, particularly sub-genotype A3 in Cameroon [38]. The patients in our study were older than those of previous studies, which could explain the differences in prevalence of HBeAg encountered.

In this study, the HBeAg-negative patients were older, mostly male, mostly had normal serum ALT levels and low serum HBV DNA concentrations compared to those with positive HBeAg. These results are identical to those in the literature [10] [39] [40]. On the contrary, hepatic lesions were more severe in positive HBeAg patients, unlike in the literature. In these patients we found 69.2% of cases of fibrosis stage > F1, 15.4% of patients with cirrhosis and a detectable HBV DNA in 100% of them, with a median of viremia of 1550 × 10^3 IU/mL. Papatheodoidis et al. [41] reported that severe liver damages were rare in HBeAg-negative subjects whose serum ALT levels and HBV DNA concentrations are low. Therefore, the results of large population-based studies with mostly (85%) HBeAg-negative, HBsAg-positive people older than 30 years at recruitment have shown that the risk of severe liver damage, including cirrhosis and hepatocellular carcinoma, and mortality increased proportionally with increasing viral DNA concentrations, starting with at least 1 × 10^4 copies per mL [2] [42] [43]. Apart from the high serum HBV DNA concentrations, others cirrhosis risk factors exist: male gender and advanced age [33] [42] [44], the persistence of HBeAg, genotype C and persistent high serum ALT levels [37] [45] [46]. Only 32.8% of HBeAg-negative patients had elevated serum ALT levels and 29.7% a serum hepatitis B virus DNA levels > 2000 IU/mL in this study. These results may explain the scarcity of severe liver injury among HBeAg-negative cases in this serie.

In this study, HBV DNA was detected in 81.0% of HBsAg-positive patients. Hepatitis B viral load was ≤2000 UI/mL in 65.9% and normal serum ALT levels in 63.2%. This proportion of HBV DNA is less than those reported by Sombié et al. [23] in Ouagadougou, Burkina Faso (89.4%) and by Allain et al. [20] in Ghana (98%). However, it is greater than that reported by Valente et al. [47] in Luanda, Angola (53%). The differences in methods of detection of serum HBV DNA explain these results.

This work has limits. This is a cross-sectional study. Indeed, the lack of the monitoring of patients is a limitation to determine the clinico-virologic profile of the mutant virus infection. Only patients with serum HBV DNA levels at relatively high rates (29.7%) and elevated serum ALT levels (32.8%) above the standard at the time of the consultation have been defined by a profile. Those with fluctuations in viral replication and transaminases could not logically be well differentiated. The inactive HBV carriage could not be distinguished from others clinico-virologic profiles in the absence of scalable data, a single point measurement of HBV DNA and ALT levels. On the other hand, the data collection was difficult because of the high costs of initial examinations paid by patients without social security and because of the fear of liver biopsy.

5. Conclusion and Recommendations

This first study among HBsAg-positive patients of Hepatitis Therapeutics Committee in Yaoundé contributed to better describing chronic HBV infections in Cameroon. It reveals that 92.1% of HBsAg-positive patients monitored thereby are HBeAg-negative, mostly male, and older compared with HBeAg-positive patients; they mostly
have normal serum ALT levels and low serum hepatitis B viral load at the time of the consultation, cirrhosis seems paradoxically rare. The high prevalence of HBeAg in this study confirms that horizontal transmission is great in our milieu, so vulgarization of the Expanded Program on Immunization is needed for the prevention of HBV infection in population.

Acknowledgements

The authors thank Ms. Brigitte Wego for English editing. We thank Doctor Jean-Dominique Poveda from Laboratory Cerba, France for biological analysis, Members of the Yaoundé Hepatitis Therapeutic Committee, and Members of the Network of the Cameroon Society of Gastroenterology.

Authors Contributions

FA: study conception, design and data analysis; MK: acquisition of data, analysis and interpretation of the data; ON: statistical analyses, data interpretation and study revision; ECNN: supervision and final approval of the version to be published. All authors have read and approved the final manuscript.

Competing Interests

The authors declare there exist no competing interests.

References

ity in Chronic Hepatitis C. *Hepatology*, **24**, 289-293. [http://dx.doi.org/10.1002/hep.510240201](http://dx.doi.org/10.1002/hep.510240201)


http://dx.doi.org/10.1016/S0140-6736(09)60207-5

http://dx.doi.org/10.1111/j.1365-2893.2006.00810.x

http://dx.doi.org/10.1016/S0140-6736(09)60207-5

http://dx.doi.org/10.1053/j.gastro.2007.08.010

http://dx.doi.org/10.1053/gast.2002.33588

http://dx.doi.org/10.1099/vir.0.80922-0

http://dx.doi.org/10.1002/hep.21811

http://dx.doi.org/10.1159/000068123

http://dx.doi.org/10.1016/j.jhep.2011.11.030

http://dx.doi.org/10.1053/j.gastro.2005.11.016

http://dx.doi.org/10.1016/j.cgh.2007.06.015

http://dx.doi.org/10.1016/j.jhep.2007.11.011

http://dx.doi.org/10.1016/j.jhep.2005.03.018

http://dx.doi.org/10.1002/hep.22878

http://dx.doi.org/10.1590/S0074-02762010000800004